Baxter International INC 8-K filings

Baxter International Inc. has reclassified its Kidney Care business as a discontinued operation, retroactively adjusting prior financial statements to reflect this change.

Baxter International's North Cove facility is closed due to flooding from Hurricane Helene, impacting production and requiring remediation efforts.

Baxter International's North Cove, N.C., manufacturing facility is closed due to severe flooding from Hurricane Helene, impacting production and requiring significant recovery efforts.

Baxter International Inc. has appointed Jeffrey A. Craig, former CEO of Meritor Corporation, to its Board of Directors, effective September 9, 2024.

Baxter International's Chief Accounting Officer, Brian Stevens, has resigned, and Joel Grade, the current CFO, will serve as interim Chief Accounting Officer.

Baxter International Inc. has reached a definitive agreement to sell its Kidney Care segment to Carlyle for $3.8 billion, marking a significant step in its strategic transformation.

Baxter International Inc. reported second-quarter results that surpassed previous guidance, with sales growth across all segments and increased full-year sales and adjusted EPS guidance.

Baxter International Inc. has entered into a credit agreement for a $2.05 billion term loan to refinance existing debt and cover tax liabilities related to its Kidney Care business separation.

Baxter International's stockholders approved an amended incentive plan and changes to the company's certificate of incorporation at their 2024 annual meeting.

Baxter International reported first-quarter 2024 results that exceeded expectations, driven by strong sales growth and operational execution, leading to an increased full-year outlook.

Baxter International Inc. has amended its credit agreements to increase the maximum net leverage ratio and reduce its revolving credit facility, reflecting strategic financial adjustments.

Baxter International is considering a potential sale of its Kidney Care business to private equity investors as an alternative to the previously announced spinoff.

Baxter International's fourth-quarter results showed a 4% sales increase, while full-year results included a net loss from continuing operations, alongside progress on strategic initiatives.